Oncology

An analysis by Kaiser Health News found that Medicaid incurred billions of dollars in extra spending as a result of price increases for hundreds of common drugs from 2015 to 2016, including decades-old branded drugs and generics used to treat cancer.

A retrospective study in patients with newly diagnosed cancer has identified an increased risk of cardiovascular (CV) abnormalities that are aggravated by cancer stage.

UnitedHealth is currently involved in 2 types of value-based contracts with its provider partners, but it has seen more success with one compared with the other, explained Lee N. Newcomer, MD, MHA, senior vice president of oncology and genetics at UnitedHealthcare.

This meeting presents unique perspectives on emerging topics in managed care from today’s leading experts

A community oncologist's perspective on the advantages and challenges with precision medicine.

A reaction to Institute for Clinical and Economic Review's value assessment framework by Eleanor M. Perfetto, PhD, MS, of The National Health Council.

A new study indicates there are persistent socioeconomic disparities in the rates of women who receive breast reconstruction surgery after undergoing a mastectomy to treat their breast cancer.

Patient reported data can be a reliable source of information to ascertain comorbidities in patients with prostate cancer, says JAMA Oncology study.

A study in JAMA Oncology has found that unpreparedness for treatment-related expenses among patients being treated for cancer can bear upon the patient’s future decision-making.

Genetic counselors (GCs) increasingly serve a variety of roles across the healthcare spectrum, including test utilization management. Our data show that utilizing the expertise of GCs reduced test order errors, improved patient outcomes, and resulted in significant cost savings to the healthcare system.

As we shift to the precision-medicine model of cancer care, it is essential to develop a scalable system that can deliver these care solutions in a patient-centered, economically sustainable way.

The Institute for Clinical and Economic Review (ICER) has released a draft version of their scoping document that will compare the clinical effectiveness and value of 2 chimeric antigen receptor (CAR)-T cell treatments being reviewed by the FDA.

MimiVax announced that its immunotherapy vaccine SurVaxM, which is being tested in clinical trials for glioblastoma, has been designated an orphan drug by the FDA.

The Bonnie Addario Lung Cancer Foundation has developed a registry that can serve as a repository for data on patients with lung cancer-a means to empower patients and assist care providers to deliver personalized medicine in a patient-centered manner.

Precision medicine is increasingly being utilized in oncology. Aurora Health Care has implemented Syapse software to integrate molecular data into the electronic health record to accommodate precision medicine findings.

The results of a phase 2 study that explored the effects of luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) were presented at the 22nd Congress of the European Hematology Association by Acceleron Pharma Inc. The company is developing the drug with Celgene.

Treatment decisions could be assisted through molecular profiling, which would allow patients and oncologists to evaluate the biological features of the tumor.

New research has identified a gene that enables paclitaxel to spread cancer to the lungs even as it shrinks tumors in the breast.

An update on the latest developments in the world of oncology care: product approvals, clinical developments, health policy changes, and more.

New research has found that the steady increase in the price of targeted oral anticancer medications is washing out the potential for savings that patients would experience in their out-of-pocket payments following closure of the Medicare Part D coverage gap.

Amidst news of Senator John McCain’s glioblastoma diagnosis, a recent discussion between 2 neuro-oncology researchers explored the reasons why this aggressive brain tumor is so difficult to manage, and outlined the ongoing investigations into possible therapies.

There’s a lot happening in clinical practice with immunotherapy treatments: expanded indications for nivolumab and ipilimumab, biomarkers to judge patient response to combinations, and developments with CAR-T.

Provider roles in team-based care in oncology need clarity, and now, results from a new study affirm the confusion experience by patients treated for breast cancer on who should lead their care posttreatment.

The approval follows a review of phase 2 results from CheckMate-142.

The new immunotherapy of chimeric antigen receptor (CAR)-T cells has demonstrated the ability to increase clinical remission in multiple myeloma patients by targeting the B-cell maturation protein that participates in disease progression.